NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Sun Pharma Advanced Research Company Limited (NSE: SPARC)

SPARC Technical Analysis
As on 25th Jan 2022 SPARC Share Price closed @ 320.95 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 244.34 & Strong Buy for SHORT-TERM with Stoploss of 275.57 we also expect STOCK to react on Following IMPORTANT LEVELS.

SPARC Share Price

Open 305.00 Change Price %
High 328.90 1 Day 14.50 4.73
Low 303.05 1 Week 6.45 2.05
Close 320.95 1 Month 74.70 30.34
Volume 1158248 1 Year 136.80 74.29
52 Week High 337.85 | 52 Week Low 141.00
NSE INDIA Most Active Stocks
IDEA 11.30 3.20%
VISESHINFO 1.55 3.33%
JPPOWER 9.05 2.84%
SUZLON 11.00 -0.90%
ZOMATO 100.45 9.96%
YESBANK 13.60 1.12%
BANKBARODA 98.50 6.37%
PNB 39.40 3.68%
ALOKINDS 29.70 2.77%
INVENTURE 5.45 -4.39%
NSE INDIA Top Gainers Stocks
SALONA 327.00 20.00%
SHARDACROP 525.35 20.00%
AMBICAAGAR 34.05 18.85%
PRESSMN 48.65 16.67%
CORALFINAC 49.85 14.60%
TRITURBINE 214.30 14.42%
OMAXE 93.10 13.95%
ARMANFIN 792.95 13.76%
ORBTEXP 100.00 13.44%
BIL 304.25 12.31%
NSE INDIA Top Losers Stocks
LUXIND 2813.70 -20.00%
MOKSH 31.50 -16.89%
INDIAMART 5005.00 -14.27%
APLAPOLLO 861.90 -8.20%
NORBTEAEXP 9.05 -7.65%
IGPL 651.45 -6.29%
DEEPAKNTR 2216.00 -6.25%
CARTRADE 721.25 -6.12%
HATSUN 1034.35 -5.88%
NAZARA 2267.20 -5.00%
Daily Charts
Intraday Charts
Whats New @
Free Analysis
SPARC Important Levels Intraday
SPARC Target for Month January
4th UP TARGET388.45
3rd UP TARGET355.88
2nd UP TARGET335.75
1st UP TARGET315.62
1st DOWN TARGET258.18
2nd DOWN TARGET238.05
3rd DOWN TARGET217.92
4th DOWN TARGET185.35
SPARC Weekly Target
4th UP TARGET375.24
3rd UP TARGET358.21
2nd UP TARGET347.69
1st UP TARGET337.16
1st DOWN TARGET307.14
2nd DOWN TARGET296.61
3rd DOWN TARGET286.09
4th DOWN TARGET269.06
SPARC Target for Year 2022
4th UP TARGET616.42
3rd UP TARGET510.74
2nd UP TARGET445.42
1st UP TARGET380.1
1st DOWN TARGET193.71
2nd DOWN TARGET128.38
3rd DOWN TARGET63.06
4th DOWN TARGET-42.62
SPARC Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is Below 30 Over Sold
MFI (14) MFI is 45.67 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 144.76
10 Day Avg Volume Traded -47.32 % Less then 10 Day Average Volume
SPARC Other Details
Segment EQ
Market Capital 74794024960.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
SPARC Address
SPARC Latest News
Your Comments and Response on Sun Pharma Advanced Research Company Limited
SPARC Business Profile
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited Address: 17-B, Mahal Industrial Estate, Mumbai, India, 400093
2005-2021 All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service